Trial: 202201161

A Phase I, Open-Label, Multicenter Study of FT538 in Combination with Monoclonal Antibodies in Subjects with Advanced Solid Tumors

Phase

I (Cancer Control)

Principal Investigator

Johanns, Tanner

Disease Site

Breast; Larynx; Lip, Oral Cavity and Pharynx; Lung; Stomach; Urinary Bladder

Learn more about this study at: clinicaltrials.gov